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Background: With development of chemoradiotherapy for pancreatic carcinoma, borderline resectable or initially
unresectable cases sometimes become operable after long-term intensive chemoradiotherapy. However, there is
no established strategy for adjuvant surgery with respect to whether the surgical resection should be extensive or
downsized accordingly with diminished disease areas following response to chemoradiotherapy.
Methods: The clinical and pathological aspects of 18 patients with initially unresectable pancreatic cancer who
underwent adjuvant surgery after chemo(radio)therapy in our department from 2007 were evaluated.
Results: Overall survival from initial treatment was much better for patients with R0 resection than for patients with
R1/2 resection. In two of three patients who had complete improvement of plexus (PL) invasion after
chemo(radio)therapy, there had still remained pathological plexus invasion. It was shown that tumors did not shrink
continuously from the tumor front, but parts remained discontinuously at the distal portion in the process of tumor
regression by chemo(radio)therapy.
Conclusions: In adjuvant surgery for patients with locally advanced pancreatic cancer, the potential risk of residual
cancer in the regression area following chemoradiotherapy should be considered. Achieving R0 resection will lead
to an improved prognosis, and it is necessary to consider how well the extent of resection is after a favorable
response to chemoradiotherapy.
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Pancreatic carcinoma is a disease with a very poor prog-
nosis. Although surgery is the only curative option for
this disease, only 20 % of patients can be treated surgically
[1]. The prognosis of patients with unresectable disease is
significantly worse than that of patients with resectable
disease. In the past, various treatments for unresectable
pancreatic carcinoma had been adopted, but prognosis in
patients with unresectable pancreatic carcinoma continues
to be disappointing [2, 3]. Recently, with the development
of chemoradiotherapy for pancreatic carcinoma, “border-
line resectable” or “initially unresectable” cases sometimes
become operable after long-term, intensive chemoradio-
therapy [4, 5]. We have previously reported the outcomes* Correspondence: htakano1231@yahoo.co.jp
Department of Gastroenterological Surgery II, Hokkaido University Graduate
School of Medicine, N-15 W-7, Sapporo, Hokkaido 060-8638, Japan
© 2015 Takano et al. This is an Open Access a
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/of adjuvant surgery for initially unresectable pancreatic
carcinoma with long-term chemoradiotherapy [6]. We de-
fined “adjuvant surgery” as radical surgery for initially
unresectable cases of pancreatic carcinoma which had a
well response to chemo(radio)therapy without original in-
tent to proceed to resection. There are several reports
showing a correlation between prognosis and neural
invasion or histopathological grading after neoadjuvant
chemoradiotherapy of patients with pancreatic carcinoma
[7, 8]. However, there is no established strategy for “adju-
vant surgery” with respect to whether the surgery should
be extensive or whether the surgical resection could be
downsized to correspond to the diminished disease areas
following response to chemoradiotherapy.
Our surgical strategy for initially unresectable patients
with a long-term favorable response to chemo(radio)-
therapy included the resection area initially affected byrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient characteristics
Characteristics 2007–2013 n = 18
Age (years) 63 (43–68)
Sex Male 8
Female 10
Tumor location Ph 7
Pb 8
Pt 3
Reason for initially unresectable Locally advanced 13
metastatic 5






Ph pancreas head, Pb pancreas body, Pt pancreas tail, SD stable disease, PR
partial response, CR complete response
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remained or not in the area where suspected involved le-
sion had improved on imaging with good response to
chemo(radio)therapy. In this report, the suitability of our
surgical strategy for initially unresectable pancreatic car-
cinoma following chemoradiotherapy was evaluated based
on the pathological analysis of the resected specimens.
Methods
Patients
From July 2007 to April 2013, surgery was performed
following chemo(radio)therapy for 18 patients with ini-
tially unresectable pancreatic carcinoma in our depart-
ment. Surgical indications for resectable tumors were
determined based on the following criteria: no distant
metastasis, no extension to the common hepatic artery
(CHA) or the superior mesenteric artery (SMA) (head of
the pancreas), and no extension to the gastro-duodenal
artery (GDA) or the SMA (body and tail of the pan-
creas). For borderline resectable tumors, the surgical in-
dications were based on the following criteria: no distant
metastasis and extension to half around plexus invasion
of the SMA. Other tumors were deemed unresectable.
Patients with unresectable tumors subsequently under-
went chemo(radio)therapy. Resectability of the tumors
was determined by imaging and intraoperative findings
and then radical surgery was performed, in principle, six
or more months after the start of the initial treatment.
Imaging diagnosis was done by a radiologist, surgeon,
gastroenterologist, and an echo technician at a Cancer
Board conference. In this study, all 18 patients were
initially diagnosed unresectable tumors through this
process. At the adjuvant surgery, our operative proced-
ure included the resection area initially affected by the
tumor. This study was approved by the Institutional Eth-
ics Committee of Hokkaido University Hospital.
Assessment of clinical and pathological efficacies after
chemoradiotherapy
Radiological assessment after initial treatment was per-
formed according to Response Evaluation Criteria In Solid
Tumors (RECIST) [9]. The pathological effect of preopera-
tive therapy was assessed by Evans grading system [10].
These assessments were done by a radiologist, surgeon,
gastroenterologist, pathologist, and an echo technician at
a Cancer Board conference and at a clinicopathological
conference, respectively.
Survival analysis
Overall patient survival was calculated from the date of
initial treatment to the date of last follow-up (censored)
or the date of patient death (event). Differences in
survival times between patient subgroups were analyzed
using the log-rank test. Survival probabilities werecalculated using the Kaplan-Meier method. In all tests,
statistical significance was set at P < 0.05. All analyses
were performed using JMP® 10 software.
Results
Patients’ characteristics
Patients’ data and the perioperative data are shown in
Tables 1 and 2. The median age of the 18 patients was
63 years (range: 43–68 years). The numbers of males
and females were nearly equal. The tumor location was
the head of the pancreas in 7 patients and the pancreatic
body or tail in 11 patients. Histological tumor types of
all patients before starting treatment were invasive ductal
adenocarcinoma. Tumors were initially unresectable due
to distant metastasis (hepatic metastasis or para-aortic
lymph node metastasis) in 5 patients, para-aortic lymph
node metastasis in 2, hepatic metastasis in 3, and major
artery involvement in 13 patients. Of them, celiac artery
invasion in 1, GDA invasion in 4, CHA invasion in 4,
SMA invasion in 3, and portal vein (PV) tumor thrombus
in 1 patient, respectively. We regarded these 13 patients
who had invasion to major vessels and had no distant me-
tastasis as the locally advanced cases. All patients were ini-
tially given chemo(radio)therapy. The treatment regimens
are shown in Table 3. All 18 patients underwent chemo-
therapy including gemcitabine (GEM); 4 patients were
treated with chemoradiotherapy. The median period for
preoperative therapy was 9 months (range: 6–44 months).
Surgical procedures performed
Subtotal stomach-preserving pancreaticoduodenectomy
(SSPPD) was performed for 7 patients, distal pancreatec-
tomy with en bloc celiac axis resection (DP-CAR) was
Table 2 Perioperative data
Postoperative date 2007–2013 n = 18




Operation time (min) 418 (200–879)
Blood loss (ml) 905 (330–3200)
Complication Total 11 (61 %)
Pancreatic fistula 4 (22 %)
SSI 4 (22 %)
Ischemic gastritis 1 (5 %)
Hospital stay (days) 30 (12–97)
Mortality 0





Residual tumor R0 15
R1 2
R2 1
SSPPD subtotal stomach-preserving pancreaticoduodenectomy, DP-CAR distal
pancreatectomy with en bloc celiac axis resection, DP distal pancreatectomy,
TP-CAR total pancreatectomy with en bloc celiac axis resection
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bloc celiac axis resection (TP-CAR) was performed for 1
patient, and distal pancreatectomy (DP) was performed
for 3 patients. SSPPD was performed using the modified
Child method. Concomitant vascular resection was ba-
sically performed if main vascular invasion or plexus in-
vasion was suspected, except for the SMA. The SMA
nerve plexus was removed circumferentially from the
root of the SMA longitudinally along to the branch of
the inferior pancreaticoduodenal artery in DP-CAR.
Among the 18 patients, there were patients with main ves-
sel resection and reconstruction including PV resectionTable 3 Neoadjuvant therapy
Chemo(radio)therapy Regimen n Period of therapy (month)
Chemotherapy (IV) GEM + S-1 10 8.5 (5–32)
GEM 1 11
Chemotherapy (TA) GEM + 5-FU 3 7/34/44
Chemoradiotherapy GEM + S-1 2 7/16
GEM + 5-FU 1 8
GEM 1 32
9 (5–44)
GEM gemcitabine, 5-FU 5-fluorouraciland reconstruction for 12 patients and arterial resection
and reconstruction for 4 patients.
Among the three patients with hepatic metastasis, two
patients initially had solitary metastasis in segment III
and segment IV, respectively. The other patient had
hepatic metastasis both in segment I and segment VIII,
resulted in no pathological evidence of malignancy
followed by concomitant partial hepatic resection. Previ-
ous two patients with solitary hepatic metastasis under-
went resection for primary lesion alone, because the
hepatic lesion was not identified in CT or completely
shrunken before surgery.
Objective tumor response to chemoradiotherapy
R0 resection was achieved in 15 patients (83 %), while
R1 resection was achieved in 2 patients (12 %) and R2
resection was achieved in 1 patient (5 %). The reasons
for R1 resection were a pathologically positive diagnosis
at the PV stump and a pathologically positive diagnosis
at the arterial plexus around the SMA, respectively. And
the reason for R2 resection was peritoneal metastasis
identified just before abdominal closure.
Using Evans grading system for tumor response, 4 pa-
tients had grade I, 6 patients had grade IIa, 5 patients
had grade IIb, 1 patient had grade III, and 2 patients had
grade IV. Based on RECIST, 13 patients had partial re-
sponse (PR), and 5 patients had stable disease (SD). No
patients had complete response (CR), but 2 patients had
pathological CR.
Improvement of arterial plexus invasion on CT imaging
over time
Of the 18 patients, 12 patients (66 %) were initially diag-
nosed as having unresectable disease with arterial plexus
invasion around the CA in 1 patient, the GDA in 4
patients, the SMA in 3 patients with pancreatic body
cancer, and the CHA in 4 patients with head of the
pancreas cancer. After the chemoradiotherapy, these
findings on CT imaging had improved with the plexus
around the artery of all patients. These fields, initially
considered to include cancer cells, were totally resected
in an en bloc-wise manner using already described pro-
cedures. Among them, 2 out of 3 patients in complete
improvement after chemoradiotherapy and 7 out of 9
patients in partial improvement had still remained patho-
logical plexus invasion (Table 4). Here, we show one
characteristic case (no. 10 in Table 4) that was initially di-
agnosed as having unresectable disease with invasion to
the plexus around the SMA. After chemotherapy includ-
ing GEM and TS-1 for 15 months, adjuvant surgery was
performed because PR was achieved (Fig. 1). CT scan after
chemotherapy showed tumor shrinkage, which was amen-
able to radical resection by DP. However, DP-CAR was
performed because of the policy described above. The



















1 Pb Ce DP-CAR Ce Partial PLce (+) R1 44 DRD
2 Pb GDA DP-CAR Ce Partial PLce, cha (+) R0 54 AFD
3 Pb GDA DP-CAR Ce, PV Partial PL (−) R0 92 AFD
4 Pb GDA DP-CAR Ce, PV Partial PLcha, sma (+) R0 55 AFD
5 Pb GDA TP-CAR Ce, GDA, PV Partial PLce, sma (+) R0 67 AFD
6 Pb SMA DP-CAR Ce, PV Partial PLspa (+) R0 91 AFD
7 Ph CHA SSPPD PV Completely PL (−) R0 63 DRD
8 Ph CHA, PHA SSPPD CHA, PHA, RHA, PV Partial PL (−) R0 31 ARD
9 Ph CHA SSPPD CHA, PV Partial PLcha (+) R0 18 DRD
10 Pb SMA DP-CAR Ce, PV Completely PLce (+) R0 32 AFD
11 Pb SMA DP-CAR Ce, PV Completely PLce (+) R0 15 ARD
12 Ph CHA SSPPD CHA, LHA, MHA, PV Partial PLcha (+) R0 11 AFD
Ce ceriac artery, GDA gastro-duodenal artery, CHA common hepatic artery, PHA proper hepatic artery, RHA right hepatic artery, LHA left hepatic artery, MHA middle
hepatic artery, PV portal vein, AFD alive free of disease, ARD alive with recurrent disease, DRD dead of recurrent disease
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cells remaining around the celiac artery discontinu-
ously (Fig. 2).
Clinical factors associated with overall survival
Overall survival of all patients is shown in Fig. 3. The me-
dian follow-up time from initial treatment in all 18 patients
was 39 months, and the 5-year survival rate was 60.3 %.Fig. 1 CT scan shows tumor invading to the SMA and CA (above). CT scan
indicate tumor invasion to the SMA or CAThe survival from initial treatment was significantly worse
for patients with metastatic disease than for patients with
locally advanced disease (P = 0.006) (Fig. 4).
Survival from initial treatment was much better for
patients with R0 resection than for patients with R1/2
resection (P = 0.002) (Fig. 5).
Examining the pathology, there was a significant differ-
ence in the prognosis between Evans grade I-IIa andshows the tumor decreased by chemotherapy (below). White arrows
Fig. 2 Histopathological mapping on the macroscopic section at the plexus around the CA, indicating residual cancer cells at the plexus around
the CA (left, area encircled with solid line). hematoxylin-eosin staining showed the residual cancer cells present at the area encircled with the
broken line (right)
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significant difference in the prognosis between patients
with and without plexus invasion (P = 0.750).
Discussion
The prognosis of patients with unresectable pancreatic
cancer is extremely poor, and development of new
anti-cancer drugs including molecular target inhibitors
has been in progress. Among clinical trials worldwide
[11–17], several anti-cancer agents have been reported
to have better response rates and 2-year survival rates
with chemotherapy alone (41.9–81.3 % and 23.5–27.1 %,
respectively) [18, 19]. However, there have been few
cases with 5-year survival treated by chemoradiotherapyFig. 3 Overall survival from initial treatment of all patients. The 5-year survi
39 months (range: 11–92 months)alone. Therefore, we have performed adjuvant surgery
for selected cases with a long-term favorable response to
chemoradiotherapy since 2006. Satoi et al. reported, in
their Project01 study by the Japanese Society of Hepato-
Biliary-Pancreatic Surgery, that the overall survival rate
from the initial treatment with adjuvant surgery was
higher than that with non-surgical anti-cancer treatment
in patients who received chemoradiation therapy for
more than 8 months [20]. Deyali reported in their series
of 20 patients who were surgically resected after neoad-
juvant chemotherapy that there was a correlation be-
tween patient prognosis and Evans grade between Evans
grade I-IIb and grade III-IV [8]. Although the preopera-
tive factors that could predict patient prognosis were notval rate is 60.3 %. The median follow-up time from initial treatment is
Fig. 4 Overall survival beginning at initial treatment in patients with locally advanced disease (T) or metastatic disease (M) as the reason for initial
unresectability. P = 0.006
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the surgical intervention by preoperative biomarkers, be-
cause it is not clear whether the operation is truly good
for patients with a good response to chemotherapy. A
further prospective study is warranted in the future.
In the present series of 18 cases, the 5-year survival
rate from initial treatment was 60.3 %, and there were 2
cases who survived more than 5 years after the operation.
Surgical margin-negative was a significant predictor of a
good prognosis. The period of preoperative treatment of
these patients other than the R0 operation was 5–11
months, but it is unclear whether R0 resection is pos-
sible if the preoperative treatment period is increased.Fig. 5 Overall survival beginning at initial treatment in patients with R0 resConsidering patients with R0 resection, the R0 rate of
patients with distant metastasis was 60 % (3/5) and that
with locally advanced disease was 92 % (12/13). There-
fore, adjuvant surgery might be appropriate for patients
with locally advanced pancreatic cancer, and it is im-
portant to achieve R0 resection. For hepatic metastasis,
only one patient underwent concomitant hepatic resec-
tion with no pathological finding of malignancy. Other
two patients did not undergo hepatic resection because
of no findings of hepatic metastasis in CT before sur-
gery. In terms of postoperative disease prognosis for the
three patients with initial hepatic metastasis, one patient
who underwent hepatic resection with no pathologicalection or R1/2 resection. P = 0.002
Fig. 6 Overall survival beginning at initial treatment in patients with Evans grade I-IIa or grade IIb-IV. P = 0.047
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node recurrence in 21 months after surgery. Other two
patients without hepatic tumors after chemoradiother-
apy developed multiple liver metastases including initial
site in 4 months or 2 months, respectively, after primary
site resection. The fact showed that they might have
partial response for hepatic metastasis which was too
small to detect in CT but not always showed complete
response.
This was a retrospective analysis, so it is not clear
whether a similar prognosis could be obtained if chemo-
therapy was continued in the patients with adjuvant
surgery. Further study is needed to decide whether sur-
gery should be performed after chemoradiotherapy in
every case.
Regarding the surgical strategy following chemotherapy
for initially unresectable pancreatic cancer, the extent of
resection remains controversial. Whether the shrunken or
arrested area which might have well responded to the che-
moradiotherapy should also be included in the scheduled
resection area is of the greatest interest. Although these
kinds of surgical strategies concerning resection area after
neoadjuvant chemoradiotherapy are well established in
other cancers [21, 22], it is still controversial for initially
unresectable pancreatic cancer. For pancreatic cancer,
there have been only several reports of a small number of
patients and limited cases with surgical procedures.
Furthermore, there are few reports that suggest an
appropriate treatment strategy, including the extent of
resection for the initially unresectable cases after
chemoradiotherapy.
In our department, we resect the area initially affected
by tumor and regional major vessels even if tumor
shrinkage was obtained and perineural invasion aroundthe artery on imaging modality was improved by initial
treatment. As shown in one characteristic case that had
undergone DP-CAR with dissection of the initially sus-
pected area with perivascular neural invasion, clear evi-
dence was shown for the first time that the tumor did
not shrink linearly or continuously from the tumor front
but that part of it often remained discontinuously at the
distal portion in the process of tumor regression by
chemotherapy. It is unknown how remaining tumor cells
in this way can affect recurrence or a patient’s prognosis.
Because of the good prognosis of patients with R0 resec-
tion, it has become clear from the pathological aspects
that the operative procedure including fields initially
affected by tumor should be concomitantly resected as
much as possible, even if arterial resection and recon-
struction are indicated.
There are some reports on the pros and cons of add-
itional arterial resection, but satisfactory results have not
been obtained for SMA resection, with a high rate of
surgery-related mortality [23, 24]. Therefore, in our
department, we perform additional arterial resection
actively only for non-SMA cases. In the present study, 4
of the 18 patients underwent arterial resection and re-
construction, and R0 resection was achieved for all 4 pa-
tients. However, accumulation of further cases is needed
to consider the long-term results for patients with arter-
ial resection.
The limitations of this study were, firstly, the small
number of the cases, secondly, selection vias with which
we indicated surgery for patients who had favorable
response to chemo(radio)therapy, and lastly, the retro-
spective nature of the study design. Therefore, statistical
analysis in this study might be better interpreted as a
trend instead of a statistical significance. And this study
Takano et al. World Journal of Surgical Oncology  (2015) 13:209 Page 8 of 8is the retrospective study for patients with unresectable
pancreatic carcinoma. Future prospective study should
be performed to clarify whether to continue chemother-
apy or indicate radical R0 operation for patients with
good response to chemo(radio)therapy.
Conclusions
In conclusion, in adjuvant surgery for patients with lo-
cally advanced pancreatic cancer, achieving R0 resection
will improve the prognosis. Because of the potent re-
sidual cancer cells at the initial tumor front and the limi-
tations of imaging diagnosis, it is necessary to consider
how well the extent of resection is after a favorable re-
sponse to chemo(radio)therapy.
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